RxDoctor Payments Data

Shiu Kwok, MD

Ophthalmology · San Francisco, CANPI 1457345613

Payments from drug & device makers

$1,469in general payments, 2019–2025

Across 39 payments — averaging $37.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$324
  • Gilead$231
  • Aerie Pharmaceuticals, Inc.$224
  • Novartis$165
  • Carl Zeiss Meditec, Inc.$126
  • Kala Pharmaceuticals, Inc.$124
  • plus $275 from 6 others

What the payments were for

  • Food & beverage$1,44698%
  • Education$232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,469 in reported general payments places this provider in the 50th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$198,552
Medicare patients
371
Services billed
1,670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine90$131,721
LumiganBimatoprost261$123,992
Alphagan PBrimonidine Tartrate287$107,638
Brimonidine Tartrate442$58,659
Bromfenac Sodium64$47,669
Cyclosporine68$43,953
Lotemax SmLoteprednol Etabonate90$38,618
ProlensaBromfenac Sodium24$21,291
XiidraLifitegrast11$18,028
CombiganBrimonidine Tartrate/Timolol23$9,738
BesivanceBesifloxacin Hcl26$7,621
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol22$6,604
Prednisolone Acetate85$5,783
Pilocarpine Hcl26$2,761
Ciprofloxacin Hcl116$2,324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$86$373,089661 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Besivance$324$67,529140 claims
Bausch & Lomb Americas Inc.Xiidra$37$18,02811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →